MONROVIA, Calif. , March 16, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Kuch , Vice President

MONROVIA, Calif. , March 2, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the completion of an underwritten public offering of 8,625,000 shares of its common stock, including 1,125,000 shares sold pursuant to the full exercise of an option previously granted to the underwriters

MONROVIA, Calif. , Feb. 25, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock, offered at a price to the public of $14.25 per share. The gross proceeds from this offering to Xencor are expected to

MONROVIA, Calif. , Feb. 23, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR) today announced that it intends to offer and sell, subject to market and other conditions, up to 5,500,000 shares of its common stock in an underwritten public offering. Xencor expects to grant the underwriters a 30-day

Conference call to be held today at 4:30 p.m. ET

MONROVIA, Calif. , Feb. 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and

MONROVIA, Calif. , Feb. 5, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases and cancer, today announced that it will webcast presentations

-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort--Autoimmune disease-modifying activity demonstrated by targeting FcgRIIb (CD32b)--Clinical trial for rare autoimmune disorder IgG4-related disease (IgG4-RD) planned for 2015--Conference call today at 8:30 a.m. ET-

- 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg -- Dose limiting toxicity of thrombocytopenia observed at 3.0 mg/kg -- Enrollment continues in Part 2 of trial for high IgE subjects -- Conference call today at 8:30 a.m. ET -

MONROVIA, Calif. , Dec. 18, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that it has entered into a